Evidence-based peptide-based formulas are associated with improved clinical outcomes and health economics.
Peptamen® Formulas and Compleat® Peptide 1.5 formulas are shown to deliver clinical and heath economic benefits such as decreased intolerance symptoms and decreased healthcare resource utilization.
A recent retrospective study showed Peptamen Junior® formulas were associated with better GI tolerance and significant reductions in Healthcare Resource Utilization in pediatric patients with GERD and gastroparesis.
Use of Peptamen® formulas in critically ill patients was associated with lower GI intolerance and greater glycemic control, relative to use of other formulas.
In a recent retrospective study, Compleat® Peptide 1.5 and Compleat Pediatric® Peptide 1.5 were associated with reductions in inpatient visits and outpatient visits in the 6 months post-hospital discharge compared to the 6 months prior to hospital discharge.
In two separate retrospective observational studies Compleat® Peptide 1.5 and Compleat® Pediatric Peptide 1.5 were associated with significant reductions in GI intolerance symptoms.